HeyJaredDeborah Brauser
- Indexed articles, last 90 days
- 14
- Latest publication
- Sep 29, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 10, 2026
Latest articles
First Time-Restricted Eating Trial in HD Shows Promise (opens the original)
Read excerpt
Time-restricted eating (TRE, or intermittent fasting) is safe and tolerable in patients with early-stage Huntington disease (HD) and was associated with improved cognitive and motor function, a new pilot trial suggested. The diet was also linked to a decrease in plasma neurofilament light chain (NfL) levels, an indicator of slower disease progression. TRE has shown promise in animal models of HD, but this 12-week trial marks the first time the diet has been studied in humans. Although HD is know
FDA Approves First-In-Class Med for Parkinson's Disease (opens the original)
Read excerpt
The FDA has approved tavapadon (JUVMO, AbbVie) tablets for adults with Parkinson's disease (PD), the first and only selective D1/D5 receptor agonist approved for this indication. The approval was based on data from three pivotal phase 3 studies in the TEMPO clinical trial program. As reported by Medscape Medical News, preliminary findings from TEMPO 1 and TEMPO 2 were presented at the American Academy of Neurology 2025 annual meeting. Among 529 patients in TEMPO 1, those who received the active
Novel First-in-Class Drug Promising in Early ADHD Study (opens the original)
Read excerpt
The novel orexin-2 receptor agonist ALKS 7290 (Alkermes) showed promise for treating adult attention-deficit hyperactivity disorder (ADHD) in early research, topline results from a phase 1B proof-of-concept study suggest. The findings from the trial showed what the company called “clinically meaningful” improvement in symptoms of ADHD from baseline to day 14 after treatment with a 20- or 50-mg dose of the drug. Improvements, as measured on the Adult ADHD Investigator Symptom Rating Scale (AISRS)
Pollutant Exposure Tied to Increased Suicide Risk (opens the original)
Read excerpt
Air pollutant exposure, especially to small particulate matter 2.5 (PM2.5) and PM10, is associated with increased risk for suicide outcomes, new research suggested. A meta-analysis and review of 45 studies showed that short-term exposure to PM10, long-term exposure to nitrogen dioxide, and short- and long-term exposure to PM2.5 were all significantly linked to elevated risk for suicidal ideation, attempted suicide, and death by suicide. Although positive associations with these outcomes were obs
Which Rx Is Best for ADHD Plus Stimulant Use Disorder? (opens the original)
Read excerpt
Stimulant-based pharmacotherapies were associated with significant alleviation of symptoms in patients with co-occurring attention-deficit/hyperactivity disorder (ADHD) and stimulant use disorder compared with placebo, new research suggested. A meta-analysis of six randomized controlled trials (RCTs) and more than 400 adult patients with both disorders showed that methylphenidate and mixed amphetamine salts (MAS), especially high-dose methylphenidate, were linked to greater improvement in ADHD s
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.